Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: Influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV89.6P infection

Vaccine

Volumn 26, Issue 26, 2008, Pages 3312-3321

  Florese, Ruth H ^a   Wiseman, Roger W ^b   Venzon, David ^a   Karl, Julie A ^b   Demberg, Thorsten ^a   Larsen, Kay ^c   Flanary, Leon ^c   Kalyanaraman, V S ^d   Pal, Ranajit ^d   Titti, Fausto ^e   Patterson, L Jean ^a   Heath, Megan J ^a   O'Connor, David H ^a   Cafaro, Aurelio ^e   Ensoli, Barbara ^e   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Washington National Primate Research Center   (United States)

^d ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV Tat vaccines; Host susceptibility resistance factors; Indian rhesus macaques; Mauritian cynomolgus macaques; MHC haplotypes

Indexed keywords

ADENOVIRUS VECTOR; HLA ANTIGEN; HLA ANTIGEN CLASS 2; HLA ANTIGEN CLASS 3; HLA ANTIGEN CLASS 5; HLA ANTIGEN CLASS 6; HLA B ANTIGEN; TRANSACTIVATOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HAPLOTYPE; IMMUNOGENICITY; INDIAN; INFECTION PREVENTION; INFECTION RESISTANCE; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MAURITIUS; MONKEY DISEASE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RHESUS MONKEY; SPECIES COMPARISON; VIREMIA; VIRUS RESISTANCE;

AIDS VACCINES; ANIMALS; DISEASE SUSCEPTIBILITY; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; MACACA FASCICULARIS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL LOAD; VIREMIA;

EID: 44749092729     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.100     Document Type: Article

References (64)

1. Arya S.K., Guo C., Josephs S.F., and Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229 (1985) 69-73
2. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., et al. The trans-activator gene of HTLV- III is essential for virus replication. Nature 320 (1986) 367-371
3. Chang H.K., Gendelman R., Lisziewicz J., Gallo R.C., and Ensoli B. Block of HIV-infection by a combination of antisense tat RNA and TAR decoys: a strategy for control of HIV-1. Gene Ther 1 (1994) 208-216
4. Dayton A.I., Sodroski J.G., Rosen C.A., Goh W.C., and Haseltine W.A. The trans-activator gene of human T-cell lymphotropic virus type III is required for replication. Cell 44 (1986) 941-947
5. Ensoli B., and Cafaro A. HIV-1 Tat vaccines. Virus Res 82 (2002) 91-101
6. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1 (1996) 960-964
7. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., and Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11 (1997) 1421-1431
8. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., and Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 345 (1990) 84-86
9. Ensoli B., Buonaguro L., Barillari G., Fiorelli V., Gendelman R., Morgan R.A., et al. Release, uptake and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67 (1993) 277-287
10. Ensoli B., Gendelman R., Markham P., Fiorelli V., Colombini S., Raffeld M., et al. Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature 371 (1994) 674-680
11. Frankel A.D., and Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55 (1988) 1189-1193
12. Conant K., Ma M., Nath A., and Major E. Extracellular human immunodeficiency virus type 1 Tat protein is associated with increaseing both NF-kB binding and protein kinase C activity in primary human astrocytes. J Virol 70 (1996) 1384-1389
13. Li C.J., Ueda Y., Shi B., Borodyansky L., Huang L., Li Y.Z., et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 94 (1997) 8116-8120
14. Huang L., Bosch I., Hofmann W., Sodroski J., and Pardee A.B. Tat protein induces human immunodeficiency type 1(HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 72 (1998) 8952-8960
15. Secchiero P., Zella D., Capitani S., Gallo R.C., and Zauli G. Extracellular HIV-1 Tat protein upregulates the expression of surface CXC-chemokine receptor 4 in resting CD4 T cells. J Immunol 162 (1999) 2427-2431
16. Li C.J., Frieman D.J., Wang C., Metelev V., and Pardee A.B. Induction of apoptosis in uninfected lymphocytes by HIV-1 tat protein. Science 268 (1995) 429-431
17. Zauli G., Gibellini D., Milani D., Mazzoni M., Borgatti P., La Placa M., et al. Human immunodeficiency type 1 Tat protein protects lymphoid, epithelial and neuronal cell lines from death by apoptosis. Cancer Res 53 (1993) 4481-4485
18. Addo M.M., Altfeld M., Rosenberg E.S., Eldridge R.L., Philips M.N., Habeeb K., et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1 infected individuals. Proc Natl Acad Sci USA 98 (2001) 1781-1786
19. Re M.C., Vignoli M., Furlini G., Gibellini D., Colangeli V., Vitone F., et al. Antibodies against full-length Tat protein and some low-molecular weight Tat-peptide correlate with low or undetectable viral load in HIV-1 seropositive patients. J Clin Virol 21 (2001) 81-89
20. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev-and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 78 (1997) 1913-1918
21. Zagury J.F., Sill A., Blattner W., Lachgar A., Le Buanec H., Richardson M., et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1 (1998) 282-292
22. Allen T.M., Mortara L., Mothé B.R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 76 (2002) 4108-4112
23. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of Simian-human immunodeficiency virus strain 89.6P challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein. J Virol 76 (2002) 3800-3809
24. Goldstein G., Manson K., Tribbick G., and Smith R. Minimization of chronic plasma viremia in rhesus smacaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33). Vaccine 18 (2000) 2789-2795
25. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with Tat toxoid attenuates disease in simian/HIV challenged macaques. Proc Natl Acad Sci USA 97 (2000) 3515-3519
26. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5 (1999) 643-650
27. Cafaro A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M., Borsetti A., et al. SHIV89.6P pathogenecity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 29 (2000) 193-208
28. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with SHIV89.6P. Vaccine 19 (2001) 2862-2877
29. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-Tat vaccinated cynomolgus monkeys. Vaccine 22 (2004) 3258-3269
30. Malkevitch N.V., and Robert-Guroff M. A call for replicating vector prime/protein boost strategies in HIV vaccine design. Exp Rev Vaccines Suppl. 3 (2004) 89-101
31. Gomez-Roman V.R., Florese R.H., Peng B., Montefiori D., Kalyanaraman V.S., Venzon D., et al. An adenovirus-based HIV subtype-B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr 43 (2006) 270-277
32. Peng B., Wang L.R., Gómez-Román V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 79 (2005) 10200-10209
33. mac251 challenge by using replicating Adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 (2004) 2212-2221
34. mac251 rectal challenge: Role of SIV-specific CD8+ T cell responses. Virology 353 (2006) 83-98
35. Krebs K.C., Jin Z.Y., Rudersdorf R., Hughes A.L., and O'Connor D.H. Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol 175 (2005) 5230-5239
36. O'Connor S.L., Blasky A.J., Pendley C.J., Becker E.A., Wiseman R.W., Karl J.A., et al. Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques. Immunogenetics 59 (2007) 449-462
37. Wiseman R.W., Wojcechowskyj J.A., Greene J.M., Blasky A.J., Gopon T., Soma T., et al. Simian immunodeficiency virus SIVmac239 infection of major histocompatibility complex-identical cyomolgus macaques from Mauritius. J Virol 81 (2007) 349-361
38. Loffredo J.T., Maxwell J., Qi Y., Glidden C.E., Borchardt G.J., Soma T., et al. Mamu-B*08-positive macaques control simian immunodeficiency virus replication. J Virol 81 (2007) 8827-8832
39. mac239 replication. J Virol 77 (2003) 2736-2740
40. O'Connor D.H., Mothe B.R., Weinfurter J.T., Fuenger S., Rehrauer W.M., Jing P., et al. Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. J Virol 77 (2003) 9029-9040
41. Pal R., Venzon D., Letvin N.L., Santra S., Montefiori D.C., Miller N.R., et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol 76 (2002) 292-302
42. Yant L.J., Friedrich T.C., Johnson R.C., May G.E., Maness N.J., Enz A.M., et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80 (2006) 5074-5077
43. Zhang Z.Q., Fu T.M., Casimiro D.R., Davies M.E., Liang X., Schleif W.A., et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol 76 (2002) 12845-12854
44. 89.6P challenge in rhesus macaques. J Virol 81 (2007) 3414-3427
45. Hel Z., Tsai W.P., Tryniszewska E., Nacsa J., Markham P.D., Lewis M.G., et al. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J Immunol 176 (2006) 85-96
46. Osterhaus A.D.M.E., van Baalen C.A., Gruters R.A., Schutten M., Siebelink C.H.J., Hulskotte E.G.J., et al. Vaccination with Rev and Tat against AIDS. Vaccine 17 (1999) 2713-2714
47. Davis D., Morein B., Akerblom L., Lovgren-Bengtsson K., van Gills M., Bogers W., et al. A recombinant prime, peptide boost vaccination strategy can focus the immune response onto more than one epitope even though these may not be immunodominant in the complex immunogen. Vaccine 15 (1997) 1661-1669
48. Zhao J., Voltan R., Peng B., Davis-Warren A., Kalyanaraman V.S., Alvord W.G., et al. Enhanced cellular immunity to SIV Gag following co-administration of adenovirus encoding wild-type or mutant HIV Tat and SIV Gag. Virology 342 (2005) 1-12
49. Reimann K.A., Li J.T., Veazey R., Halloran M., Park I.W., Karlsson G.B., et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 70 (1996) 6922-6928
50. Patterson L.J., Malkevitch N., Pinczewski J., Venzon D., Lou Y., Peng B., et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV)env/rev, gag, and or nef vaccines an d boosted with SIV gp120. J Virol 77 (2003) 8607-8620
51. Buge S.L., Richardson E., Alipanah S., Markham P., Cheng S., Kalyan N., et al. An Adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 71 (1997) 8531-8541
52. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P., et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 86 (2000) 61-70
53. Karl J.A., Wiseman R.W., Campbell K.J., Blasky A.J., Hughes A.L., Ferguson B., et al. Identification of MHC class I sequences in Chinese-origin rhesus macaques. Immunogenetics 60 (2007) 37-46
54. Harrop R., Ryan M.G., Golding H., Redchenko I., and Carroll M.M. Monitoring of human immunological responses to vaccinia virus. Methods Mol Biol 269 (2004) 243-266
55. Giraldo-Vela J.P., Rudersdorf R., Chung C., Qi Y., Wallace L.T., Bimber B., et al. The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of SIV-infected rhesus macaque elite controllers. J Virol 82 (2007) 859-870
56. Kiepiela P., Leslie A.J., Honeyborne I., Ramduth D., Thobakgale C., Chetty S., et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432 (2004) 769-774
57. Carrington M., and O'Brien S.J. The influence of HLA genotype on AIDS. Annu Rev Med 54 (2003) 535-551
58. Wojcechowskyj J.A., Yant L.J., Wiseman R.W., O'Connor S.L., and O'Connor D.H. Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes. J Virol 81 (2007) 406-410
59. Martin M.P., Gao X., Lee J., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Gen 31 (2002) 429-434
60. Qi Y., Martin M.P., Gao X., Jacobson L., Goedert J.J., Buchbinder S., et al. KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathol 2 (2006) 0741-745
61. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Gen 39 (2007) 733-740
62. Alter G., Martin M.P., Teigen N., Carr W.H., Suscovich T.J., Schneidewind A., et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 204 (2007) 3027-3036
63. Jennes W., Verheyden S., Demanet C., Adje-Toure C.A., Vuylsteke B., Nkenzasong J.N., et al. Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 177 (2006) 6588-6592
64. Reimann K.A., Parker R.A., Seaman M.S., Beaudry K., Beddall M., Peterson L., et al. Pathogenicity of Simian-human immunodeficiency virus SHIV89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 79 (2005) 8878-8885